Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +1.19%19 OCF Margin % is 15.90% as of Dec. 2025, which is 4% below its 10-year median of 16.53. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 962 Drug Manufacturers companies, Pet Pharm Biotech Co ranks better than 66.42% on this metric.
The historical rank and industry rank for Pet Pharm Biotech Co's OCF Margin % or its related term are showing as below:
ROCO:7762'
s OCF Margin % Range Over the Past 10 Years
Min: -23.53 Med: 16.53 Max: 22.1
Current: 15.45
During the past 4 years, the highest OCF Margin % of Pet Pharm Biotech Co was 22.10%. The lowest was -23.53%. And the median was 16.53%.
ROCO:7762's OCF Margin % is ranked better than 66.42% of 962
companies
in the Drug Manufacturers industry
Industry Median: 10.04
vs ROCO:7762: 15.45
Pet Pharm Biotech Co OCF Margin % Related Terms
Pet Pharm Biotech Co OCF Margin % Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a OCF Margin % of 15.90% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pet Pharm Biotech Co and its competitors. This is near median its historical median of 16.53. According to the industry distribution chart, Pet Pharm Biotech Co ranks #323 out of 962 companies in the Drug Manufacturers industry, placing it in the top 33.6%.
Is Pet Pharm Biotech Co's OCF Margin % too high?
Pet Pharm Biotech Co's current OCF Margin % of 15.90% is near median its 10-year median of 16.53. The Drug Manufacturers industry median OCF Margin % is 10.04. Pet Pharm Biotech Co's value of 15.90% is 58.4% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #323 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's OCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #323 out of 962 companies for OCF Margin %. This puts Pet Pharm Biotech Co in the upper half of its industry. The industry median OCF Margin % is 10.04. Pet Pharm Biotech Co's value of 15.90% is 58.4% above this benchmark. While the company's 10-year median is 16.53 vs. the industry median of 10.04, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current OCF Margin % of 15.90% is 58.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current OCF Margin % is 15.90%, which is near median its own 10-year median of 16.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current OCF Margin % of 15.90%. The current OCF Margin % is 15.90%, which is near median its 10-year median of 16.53 and 58.4% above the Drug Manufacturers industry median of 10.04. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current OCF Margin % is 15.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score
Get the complete analysis for ROCO:7762
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
